Coenzyme during the synthesis of many proteins involved in blood clotting and bone metabolism
| Life Stage Group | RDA/AI* (µg/d) | ULa |
|---|---|---|
| Infants | ||
| 0–6 mo | 2.0* | ND |
| 7–12 mo | 2.5* | ND |
| Children | ||
| 1–3 yr | 30* | ND |
| 4–8 yr | 55* | ND |
| Males | ||
| 9–13 yr | 60* | ND |
| 14–18 yr | 75* | ND |
| 19–30 yr | 120* | ND |
| 31–50 yr | 120* | ND |
| 50–70 yr | 120* | ND |
| >70 yr | 120* | ND |
| Females | ||
| 9–13 yr | 60* | ND |
| 14–18 yr | 75* | ND |
| 19–30 yr | 90* | ND |
| 31–50 yr | 90* | ND |
| 50–70 yr | 90* | ND |
| >70 yr | 90* | ND |
| Pregnancy | ||
| <=18 yr | 75* | ND |
| 19–30 yr | 90* | ND |
| 31–50 yr | 90* | ND |
| Lactation | ||
| <=18 yr | 75* | ND |
| 19–30 yr | 90* | ND |
| 31–50 yr | 90* | ND |
Green vegetables (collards, spinach, salad greens, broccoli), Brussels sprouts, cabbage, plant oils, and margarine
Adverse Effects of Excessive Consumption
No adverse effects associated with vitamin K consumption from food or supplements have been reported in humans or animals. This does not mean that there is no potential for adverse effects resulting from high intakes. Because data on the adverse effects of vitamin K are limited, caution may be warranted.
Patients on anticoagulant therapy should monitor vitamin K intake.